Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (PWSS)
The present invention relates to the fields of neurological and skin disorders. More specifically, the present invention provides methods and compositions for diagnosing and prognosing Sturge-Weber Syndrome (SWS), Klippel-Trenaunay-Weber Syndrome (KTWS), and Port Wine Stains (PWS). In one embodiment, a method for prognosing or monitoring treatment of a patient with SWS, KTWS and/or PWS comprises the steps of (a) providing a sample from the patient undergoing treatment; (b) determining the number of alleles in the sample comprising at least one activating somatic mutation in the guanine nucleotide-binding protein G subunit alpha (GNAQ) gene or protein; (c) comparing the number of alleles comprising the at least one somatic mutation to the number of alleles comprising the somatic mutation from a patient sample provided prior to undergoing treatment; and (d) determining that the patient is improving if there is a decrease in the number of alleles comprising the at least one somatic mutation from the sample of step (a).
1. A method for identifying a human patient as having or likely to have Sturge-Weber syndrome (SWS) comprising the steps of:
a. providing a nucleic acid sample from the human patient;
b. detecting the somatic mutation c.548G>A in the guanine nucleotide-binding protein G subunit alpha (GNAQ) gene in the nucleic acid sample, wherein the detecting step comprises (i) amplicon sequencing of a polymerase chain reaction amplicon generated using the primers set forth in SEQ ID NOS:14-15 and optionally the primers set forth in SEQ ID NOS:16-17, or (ii) polymerase chain reaction and a single base pair extension assay using a primer set forth in SEQ ID NO:3 or SEQ ID NO:4; and
c. identifying the human patient having the somatic mutation c.548G>A as having or likely to have SWS.
2. A method for monitoring treatment of a human patient with Sturge-Weber syndrome (SWS) comprising the steps of:
a. providing a sample from the human patient undergoing treatment;
b. detecting the number of alleles in the sample comprising the somatic mutation c.548G>A in the guanine nucleotide-binding protein G subunit alpha (GNAQ) gene or p.R183Q in the GNAQ protein, wherein the mutation is detected by (i) amplicon sequencing of a polymerase chain reaction amplicon generated using the primers set forth in SEQ ID NOS:14-15 and optionally the primers set forth in SEQ ID NOS:16-17, or (ii) polymerase chain reaction and a single base pair extension assay using a primer set forth in SEQ ID NO:3 or SEQ ID NO:4;
c. comparing the number of alleles comprising the somatic mutation to the number of alleles comprising the somatic mutation from the human patient sample provided prior to undergoing treatment; and
d. determining that the human patient is improving if there is a decrease in the number of alleles comprising the somatic mutation from the sample of step (a).
3. A method to monitor progress of SWS treatment in a human patient comprising (a) detecting in a test sample relative to normal sample, a somatic mutation at c.548G>A in the GNAQ gene, wherein the detecting step comprises (i) amplicon sequencing of a polymerase chain reaction amplicon generated using the primers set forth in SEQ ID NOS:14-15 and optionally the primers set forth in SEQ ID NOS:16-17, or (ii) polymerase chain reaction and a single base pair extension assay using a primer set forth in SEQ ID NO:3 or SEQ ID NO:4; (b) repeating one or more times the detecting step; and (c) identifying an increase, decrease or stable level of the mutation in the test sample over time.
4. A method for monitoring the response of a human patient with SWS to therapy comprising the steps of:
a. administering a therapy to the human patient;
b. obtaining a nucleic acid sample from the human patient; and
c. detecting a somatic mutation at c.548G>A of the GNAQ gene, wherein the detecting step comprises (i) amplicon sequencing of a polymerase chain reaction amplicon generated using the primers set forth in SEQ ID NOS:14-15 and optionally the primers set forth in SEQ ID NOS:16-17, or (ii) polymerase chain reaction and a single base pair extension assay using a primer set forth in SEQ ID NO:3 or SEQ ID NO:4.
5. A method for monitoring treatment of a human patient with Klippel-Trenaunay-Weber Syndrome (KTWS) comprising the steps of:
a. providing a sample from the human patient undergoing treatment;
b. detecting the number of alleles in the sample comprising the somatic mutation c.548G>A in the guanine nucleotide-binding protein G subunit alpha (GNAQ) gene, wherein the detecting step comprises (i) amplicon sequencing of a polymerase chain reaction amplicon generated using the primers set forth in SEQ ID NOS:14-15 and optionally the primers set forth in SEQ ID NOS:16-17, or (ii) polymerase chain reaction and a single base pair extension assay using a primer set forth in SEQ ID NO:3 or SEQ ID NO:4;
c. comparing the number of alleles comprising the somatic mutation to the number of alleles comprising the somatic mutation from the human patient sample provided prior to undergoing treatment; and
d. determining that the human patient is improving if there is a decrease in the number of alleles comprising the somatic mutation from the sample of step (a).
6. A method to monitor progress of KTWS treatment in a human patient comprising (a) detecting in a test sample relative to normal sample, a somatic mutation at c.548G>A in the GNAQ gene, wherein the detecting step comprises (i) amplicon sequencing of a polymerase chain reaction amplicon generated using the primers set forth in SEQ ID NOS:14-15 and optionally the primers set forth in SEQ ID NOS:16-17, or (ii) polymerase chain reaction and a single base pair extension assay using a primer set forth in SEQ ID NO:3 or SEQ ID NO:4; (b) repeating one or more times the detecting step; and (c) identifying an increase, decrease or stable level of the mutation in the test sample over time.
7. A method for monitoring the response of a human patient with KTWS to therapy comprising the steps of:
a. administering a therapy to the human patient;
b. obtaining a nucleic acid sample from the human patient; and
c. detecting a somatic mutation at c.548G>A of the GNAQ gene is present, wherein the detecting step comprises (i) amplicon sequencing of a polymerase chain reaction amplicon generated using the primers set forth in SEQ ID NOS:14-15 and optionally the primers set forth in SEQ ID NOS:16-17, or (ii) polymerase chain reaction and a single base pair extension assay using a primer set forth in SEQ ID NO:3 or SEQ ID NO:4.
8. A method for monitoring treatment of a human patient with Port Wine Stains (PWS) comprising the steps of:
a. providing a sample from the human patient undergoing treatment;
b. detecting the number of alleles in the sample comprising the somatic mutation c.548G>A in the guanine nucleotide-binding protein G subunit alpha (GNAQ) gene, wherein the detecting step comprises (i) amplicon sequencing of a polymerase chain reaction amplicon generated using the primers set forth in SEQ ID NOS:14-15 and optionally the primers set forth in SEQ ID NOS:16-17, or (ii) polymerase chain reaction and a single base pair extension assay using a primer set forth in SEQ ID NO:3 or SEQ ID NO:4;
c. comparing the number of alleles comprising the somatic mutation to the number of alleles comprising the somatic mutation from a human patient sample provided prior to undergoing treatment; and
d. determining that the human patient is improving if there is a decrease in the number of alleles comprising the somatic mutation from the sample of step (a).
9. A method for prognosing or monitoring treatment of a human patient with SWS, KTWS and/or PWS comprising the steps of:
a. providing a sample from the human patient undergoing treatment;
b. detecting the number of alleles in the sample comprising a somatic mutation at c.548G>A in the guanine nucleotide-binding protein G subunit alpha (GNAQ) gene, wherein the detecting step comprises (i) amplicon sequencing of a polymerase chain reaction amplicon generated using the primers set forth in SEQ ID NOS:14-15 and optionally the primers set forth in SEQ ID NOS:16-17, or (ii) polymerase chain reaction and a single base pair extension assay using a primer set forth in SEQ ID NO:3 or SEQ ID NO:4;
c. comparing the number of alleles comprising the somatic mutation to the number of alleles comprising the somatic mutation from the human patient sample provided prior to undergoing treatment; and
d. determining that the human patient is improving if there is a decrease in the number of alleles comprising the somatic mutation from the sample of step (a).